ETFs positioned on AstraZeneca PLC

Name YTD change Weight AuM
+13.19%-.--% 27,154 M€
+10.81%-.--% 2,627 M€
-.--%-.--% 22 M€
+1.61%-.--% 51 M€
+10.96%-.--% 122 M€
+2.53%-.--% 293 M€
+11.41%-.--% 3,469 M€
+10.75%-.--% 6,576 M€
-2.93%17.21% 391 M€
-2.97%15.79% 1,024 M€
-4.72%15.25% 820 M€
-2.27%13.81% 667 M€
+8.50%9.6% 106 M€
+8.62%9.6% 147 M€
+6.62%9.6% 19 M€
+11.61%9.6% 1,166 M€
+11.51%9.5% 2,462 M€
+7.95%9.5% 428 M€
+11.19%9.32% 158 M€
+10.69%9.22% 265 M€
+10.40%9.07% 935 M€
-.--%8.9% 1,190 M€
+7.86%8.9% 1,190 M€
+8.32%8.88% 38 M€
+6.08%8.88% 90 M€
+10.32%8.7% 679 M€
+11.35%8.68% 1,211 M€
+9.06%8.64% 44 M€
+9.94%8.6% 3,929 M€
+8.81%8.58% 6,358 M€
-.--%8.57% 122 M€
+11.74%8.57% 122 M€
+10.93%8.56% 4,353 M€
+11.21%8.56% 225 M€
+10.28%8.53% 54 M€
+7.13%8.39% 56 M€
+7.72%8.3% 19 M€
-.--%8.11% 114 M€
+10.23%8.11% 114 M€
+9.11%7.88% 158 M€
+10.12%7.83% 97 M€
+10.78%7.57% 22,220 M€
+11.11%7.55% 544 M€
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
  1. Stock Market
  2. Stocks
  3. AZN Stock
  4. ETFs AstraZeneca PLC
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!